Home » Market News » DirectorsTalk Highlights » Open Orphan agrees contract for Covid-19 vaccine trial
Open Orphan PLC

Open Orphan agrees contract for Covid-19 vaccine trial

Dublin-listed pharmaceutical company Open Orphan has announced a new contract with Codagenix to conduct a first human trial evaluating safety and immunogenicity of a single-dose Covid-19 vaccine.

hVIVO, part of Open Orphan, will conduct the vaccine trial for Codagenix at its quarantine facility in London.

Open Orphan said that 48 healthy young adult volunteers will take part in the trial.

Open Orphan (LON:ORPH) was founded in 2017, with the goal of rapidly building Europe’s leading pharma services company by a management team with extensive industry and financial expertise. The company comprises of two commercial specialist CRO services businesses (Venn Life Sciences and hVIVO) and is also developing a genomics data platform business (Genomic Health Data). 

To read the full news article please click here

Receive our exclusive interviews – Enter your email to stay up to date.

Disclaimer: Statements in this article should not be considered investment advice, which is best sought directly from a qualified professional.